Introduction Asthma, a heterogeneous disease, is characterized by chronic airway
inflammation and hyperreactivity. β2-adrenoreceptor agonists (β2-agonists) remain pivotal …

Introduction: A fixed-dose inhalation of a long-acting β-agonist (LABA) and inhaled
corticosteroids (ICS) is commonly recommended for moderate to severe asthmatic patients …

History suggests β agonists, the cognate ligand of the β 2 adrenoceptor, have been used as
bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment …

An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …

Beta adrenergic drugs are the most potent bronchodilators approved for clinical use in
asthma and obstructive lung disease. Among the beta agonists, the individual agents vary in …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

OBJECTIVE: To review the more recent literature addressing the issue of whether β2-
agonists can worsen asthma and/or increase the risk of severe exacerbations and death …

It is time to end our love affair with short-acting β2-agonists in asthma | European
Respiratory Society Skip to main content Main menu Home Current issue Early View …

New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear
in several European countries for treatment of asthma. This review examines currently …

Intermediate-acting inhaled β 2-agonists (eg albuterol [salbutamol]), once recommended for
round-the-clock bronchodilation, are now recommended to be used exclusively as-needed …